Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/112028
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeyabalan, J. | - |
dc.contributor.author | Viollet, B. | - |
dc.contributor.author | Smitham, P. | - |
dc.contributor.author | Ellis, S. | - |
dc.contributor.author | Zaman, G. | - |
dc.contributor.author | Bardin, C. | - |
dc.contributor.author | Goodship, A. | - |
dc.contributor.author | Roux, J. | - |
dc.contributor.author | Pierre, M. | - |
dc.contributor.author | Chenu, C. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Osteoporosis International, 2013; 24(10):2659-2670 | - |
dc.identifier.issn | 0937-941X | - |
dc.identifier.issn | 1433-2965 | - |
dc.identifier.uri | http://hdl.handle.net/2440/112028 | - |
dc.description.abstract | Summary: The present study shows no adverse effects of the anti-diabetic drug metformin on bone mass and fracture healing in rodents but demonstrates that metformin is not osteogenic in vivo, as previously proposed. Introduction: In view of the increased incidence of fractures in patients with type 2 diabetes mellitus (T2DM), we investigated the effects of metformin, a widely used T2DM therapy, on bone mass and fracture healing in vivo using two different rodent models and modes of metformin administration. Methods: We first subjected 12-week-old female C57BL/6 mice to ovariectomy (OVX). Four weeks after OVX, mice received either saline or metformin administered by gavage (100 mg/kg/daily). After 4 weeks of treatment, bone micro-architecture and cellular activity were determined in tibia by micro-CT and bone histomorphometry. In another experiment, female Wistar rats aged 3 months were given only water or metformin for 8 weeks via the drinking water (2 mg/ml). After 4 weeks of treatment, a mid-diaphyseal osteotomy was performed in the left femur. Rats were sacrificed 4 weeks after osteotomy and bone architecture analysed by micro-CT in the right tibia while fracture healing and callus volume were determined in the left femur by X-ray analysis and micro-CT, respectively. Results: In both models, our results show no significant differences in cortical and trabecular bone architecture in metformin-treated rodents compared to saline. Metformin had no effect on bone resorption but reduced bone formation rate in trabecular bone. Mean X-ray scores assessed on control and metformin fractures showed no significant differences of healing between the groups. Fracture callus volume and mineral content after 4 weeks were similar in both groups. Conclusions: Our results indicate that metformin has no effect on bone mass in vivo or fracture healing in rodents. | - |
dc.description.statementofresponsibility | J. Jeyabalan, B. Viollet, P. Smitham, S.A. Ellis, G. Zaman, C. Bardin, A. Goodship, J.P. Roux, M. Pierre, C. Chenu | - |
dc.language.iso | en | - |
dc.publisher | Springer | - |
dc.rights | © The Author(s) 2013. This article is published with open access at Springerlink.com | - |
dc.source.uri | http://dx.doi.org/10.1007/s00198-013-2371-0 | - |
dc.subject | Bone architecture; fracture healing; histomorphometry; metformin; micro-CT | - |
dc.title | The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00198-013-2371-0 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Smitham, P. [0000-0002-1481-5695] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.